Company intelligence / Profile preview
Cure Genetics
Suzhou, Jiangsu Province, Chinacuregenetics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
CGC729, an anti-CD70 CAR-NKT therapy for relapsed advanced renal cell carcinoma (RCC), has shown good safety profile and anti-tumor activity in Phase I clinical trials. This marked the first human trial using CAR-NKT therapy for RCC[9].
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Cell therapy (CAR-NKT)Gene therapy (AAV vectors)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Frametact Limited ($60 million collaboration)Boehringer Ingelheim
Beyond the preview
Go deeper on Cure Genetics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cure Genetics.